ARALEZ PHARMACEUTICALS INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
ARALEZ PHARMACEUTICALS INC. reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$19.74 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2018-05-08
- ARALEZ PHARMACEUTICALS INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2018-03-31 was -$19.74M.
- ARALEZ PHARMACEUTICALS INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2017-12-31 was -$45.77M.
- ARALEZ PHARMACEUTICALS INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2017-09-30 was -$24.44M.
- ARALEZ PHARMACEUTICALS INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2017-06-30 was -$27.52M.
- ARALEZ PHARMACEUTICALS INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2017 was -$125.20M.
- ARALEZ PHARMACEUTICALS INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2016 was -$102.98M.
- ARALEZ PHARMACEUTICALS INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2015 was -$37.78M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$19.74M 10-Q · filed 2018-05-08 | -$65.51M derived: sum of 2 quarters · filed 2018-05-08 | -$89.95M derived: sum of 3 quarters · filed 2018-05-08 | -$117.47M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-12-31 | -$45.77M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$70.21M derived: sum of 2 quarters · filed 2018-03-14 | -$97.73M derived: sum of 3 quarters · filed 2018-03-14 | -$125.20M 10-K · filed 2018-03-14 |
| 2017-09-30 | -$24.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$51.96M derived: sum of 2 quarters · filed 2017-11-09 | -$79.44M 10-Q · filed 2017-11-09 | -$110.55M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-06-30 | -$27.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$55.00M 10-Q · filed 2017-08-09 | -$86.11M derived: sum of 3 quarters · filed 2018-05-08 | -$106.71M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-03-31 | -$27.48M 10-Q · filed 2018-05-08 | -$58.59M derived: sum of 2 quarters · filed 2018-05-08 | -$79.19M derived: sum of 3 quarters · filed 2018-05-08 | |
| 2016-12-31 | -$31.12M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$51.72M derived: sum of 2 quarters · filed 2018-03-14 | -$102.98M 10-K · filed 2018-03-14 | |
| 2016-09-30 | -$20.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$71.86M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | -$51.26M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | -$37.78M 10-K · filed 2018-03-14 |